Kaandorp, J.Benders, M.Schuit, E.Rademaker, C.Oudijk, M.Porath, M.Oetomo, S.Wouters, M.van Elburg, R.Franssen, M.Bos, A.de Haan, T.Boon, J.de Boer, I.Rijnders, R.Jacobs, C.Scheepers, L.Gavilanes, D.Bloemenkamp, K.Rijken, M.et al.2016-01-052016-01-052015Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015; 100(3):F216-F2231359-29981468-2052http://hdl.handle.net/2440/97631OBJECTIVE: To determine whether maternal allopurinol treatment during suspected fetal hypoxia would reduce the release of biomarkers associated with neonatal brain damage. DESIGN: A randomised double-blind placebo controlled multicentre trial. PATIENTS: We studied women in labour at term with clinical indices of fetal hypoxia, prompting immediate delivery. SETTING: Delivery rooms of 11 Dutch hospitals. INTERVENTION: When immediate delivery was foreseen based on suspected fetal hypoxia, women were allocated to receive allopurinol 500 mg intravenous (ALLO) or placebo intravenous (CONT). MAIN OUTCOME MEASURES: Primary endpoint was the difference in cord S100ß, a tissue-specific biomarker for brain damage. RESULTS: 222 women were randomised to receive allopurinol (ALLO, n=111) or placebo (CONT, n=111). Cord S100ß was not significantly different between the two groups: 44.5 pg/mL (IQR 20.2-71.4) in the ALLO group versus 54.9 pg/mL (IQR 26.8-94.7) in the CONT group (difference in median -7.69 (95% CI -24.9 to 9.52)). Post hoc subgroup analysis showed a potential treatment effect of allopurinol on the proportion of infants with a cord S100ß value above the 75th percentile in girls (ALLO n=5 (12%) vs CONT n=10 (31%); risk ratio (RR) 0.37 (95% CI 0.14 to 0.99)) but not in boys (ALLO n=18 (32%) vs CONT n=15 (25%); RR 1.4 (95% CI 0.84 to 2.3)). Also, cord neuroketal levels were significantly lower in girls treated with allopurinol as compared with placebo treated girls: 18.0 pg/mL (95% CI 12.1 to 26.9) in the ALLO group versus 32.2 pg/mL (95% CI 22.7 to 45.7) in the CONT group (geometric mean difference -16.4 (95% CI -24.6 to -1.64)). CONCLUSIONS: Maternal treatment with allopurinol during fetal hypoxia did not significantly lower neuronal damage markers in cord blood. Post hoc analysis revealed a potential beneficial treatment effect in girls. TRIAL REGISTRATION NUMBER: NCT00189007, Dutch Trial Register NTR1383.en© 2015 BMJ Publishing GroupFetal BloodAldehydesKetonesOxypurinolAllopurinolXanthine OxidaseDinoprostEnzyme InhibitorsDouble-Blind MethodMaternal-Fetal ExchangeS100 Calcium Binding Protein beta SubunitMaternal allopurinol administration during suspected fetal hypoxia: a novel neuroprotective intervention? A multicentre randomised placebo controlled trialJournal article003001780110.1136/archdischild-2014-3067692-s2.0-84927759046163412Mol, B. [0000-0001-6887-0262] [0000-0001-8337-550X]